AI Achieves a Breakthrough in the Use of a New PHD Inhibitor to Cure Anaemia
Source-Metaverse-Post InSilico Medicine (“InSilico”), a biotechnology company driven by generative artificial intelligence (AI) and in the clinical stage, announced today that its discovery of a novel PHD inhibitor for cure anaemia was published in the Journal of Medicinal Chemistry, an ACS Publications journal that focuses on critical studies about molecular structure and biological activity. Chemistry42, a unique generative chemistry platform with over 40 carefully chosen generative models, is the driving force behind this scholarly discovery. Previous research has indicated that inhibiting prolyl hydroxylase domain enzymes (PHD) might impact basic biological processes, such as red blood cell synthesis, via controlling the HIF-α pathway, which has earned a Nobel prize. This suggests that PHD inhibition may have therapeutic promise to cure anaemia caused by chronic kidney disease. New PHD Inhibitor to Cure Anaemia With the aid of Chemistry42, Insilico’s scientists produced...